NL181654C - Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylpropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropylfenyletherderivaten. - Google Patents

Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylpropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropylfenyletherderivaten.

Info

Publication number
NL181654C
NL181654C NLAANVRAGE7500186,A NL7500186A NL181654C NL 181654 C NL181654 C NL 181654C NL 7500186 A NL7500186 A NL 7500186A NL 181654 C NL181654 C NL 181654C
Authority
NL
Netherlands
Prior art keywords
preparation
hyphylene
methylphyl
phenylpropylphenyl
methylamino
Prior art date
Application number
NLAANVRAGE7500186,A
Other languages
English (en)
Dutch (nl)
Other versions
NL181654B (nl
NL7500186A (nl
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL181654(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Publication of NL7500186A publication Critical patent/NL7500186A/xx
Publication of NL181654B publication Critical patent/NL181654B/xx
Application granted granted Critical
Publication of NL181654C publication Critical patent/NL181654C/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NLAANVRAGE7500186,A 1974-01-10 1975-01-07 Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylpropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropylfenyletherderivaten. NL181654C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (3)

Publication Number Publication Date
NL7500186A NL7500186A (nl) 1975-07-14
NL181654B NL181654B (nl) 1987-05-04
NL181654C true NL181654C (nl) 1987-10-01

Family

ID=26625843

Family Applications (2)

Application Number Title Priority Date Filing Date
NLAANVRAGE7500186,A NL181654C (nl) 1974-01-10 1975-01-07 Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylpropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropylfenyletherderivaten.
NL930108C NL930108I2 (nl) 1974-01-10 1993-06-29 Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropyletherderivaten.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL930108C NL930108I2 (nl) 1974-01-10 1993-06-29 Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropyletherderivaten.

Country Status (23)

Country Link
US (1) US4314081A (de)
JP (1) JPS5939418B2 (de)
AR (3) AR205577A1 (de)
AT (1) AT336000B (de)
BE (1) BE824255A (de)
BG (3) BG23212A3 (de)
CA (1) CA1051034A (de)
CH (1) CH609675A5 (de)
CS (1) CS189680B2 (de)
DD (1) DD118613A5 (de)
DE (1) DE2500110A1 (de)
DK (1) DK140430B (de)
ES (1) ES433720A1 (de)
FR (1) FR2257288B1 (de)
GB (1) GB1493961A (de)
IE (1) IE40346B1 (de)
NL (2) NL181654C (de)
PH (1) PH11652A (de)
RO (2) RO69763A (de)
SE (1) SE412906B (de)
SU (1) SU1005655A3 (de)
YU (3) YU36915B (de)
ZA (1) ZA7532B (de)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
CA1327795C (en) * 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
CA1337128C (en) * 1988-04-08 1995-09-26 David Wayne Robertson Propanamine derivatives
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (de) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (en) * 1991-07-01 1993-01-21 The General Hospital Corporation Invertebrate phenylethanolamine transporter and the use thereof
IL99316A (en) * 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
EP0537915B1 (de) * 1991-09-27 1995-07-12 Eli Lilly And Company N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (de) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamin-Derivate, ihre Herstellung und Verwendung
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
DE69607904T2 (de) * 1995-08-16 2000-10-05 Eli Lilly And Co., Indianapolis Potenzierung von Serotonin-Wirkstoffresponz
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CZ296282B6 (cs) * 1997-11-14 2006-02-15 Akzo Nobel N. V. Farmaceutický prostredek
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
AU2180400A (en) * 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000058262A1 (en) * 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
MXPA02001811A (es) * 1999-09-03 2002-08-06 Lilly Co Eli Metodos de uso de inhibidores de la reabsorcion de la serotonina selectivos, de inicio rapido de accion para el tratamiento de la disfuncion sexual.
WO2001044166A1 (en) 1999-12-17 2001-06-21 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US20040082666A1 (en) * 2001-03-06 2004-04-29 Mattiuz Edward Louis Inhibitor of monoamine uptake
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
EP1554572B1 (de) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
WO2003011272A1 (en) * 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
DE60220825T2 (de) * 2001-11-30 2008-03-06 Eli Lilly And Co., Indianapolis Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
NZ532065A (en) * 2001-12-11 2007-03-30 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
WO2003102158A2 (en) * 2002-05-31 2003-12-11 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2004091596A2 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
CN103788089A (zh) * 2003-09-17 2014-05-14 詹森药业有限公司 作为血清素受体调节剂的稠合杂环化合物
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2552064A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
EP1732610A2 (de) * 2004-03-26 2006-12-20 Baylor University Gezielte inhibitoren der serotonin-wiederaufname
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20080004470A1 (en) * 2004-09-27 2008-01-03 Mathad Vijayavitthal T Synthesis of Atomoxetine Hydrochloride
EP1730132A2 (de) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung pharmazeutisch unbedenklicher salze von duloxetin und zwischenprodukten davon
US7399871B2 (en) * 2005-03-08 2008-07-15 Teva Pharmaceutical Industries Ltd. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
MX2007011254A (es) * 2005-03-14 2007-10-18 Teva Pharma Proceso para la preparacion de (s)-(+)-n,n-dimetil-3-(1- naftaleniloxi)-3-(2-tienil)propanamina opticamente activa.
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
CA2603900A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
EP2317316A3 (de) 2005-07-08 2011-06-15 Braincells, Inc. Verfahren zur Identifizierung von neurogenesemodulierenden Wirkstoffen und Bedingungen
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
DK1910346T3 (da) * 2005-07-19 2019-05-27 Azevan Pharmaceuticals Inc Beta-lactamyl fenylalanin, cystein og serin vasopressin antagonist
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1838692A2 (de) * 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleat und herstellungsverfahren dafür
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
MX2007011611A (es) * 2006-01-23 2007-10-18 Teva Pharma Fumarato de dnt y metodos de preparacion de ellos.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (de) * 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
CN101448815A (zh) * 2006-05-23 2009-06-03 特瓦制药工业有限公司 度洛西汀hci多晶型物
EP2046119A2 (de) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Behandlung von psychiatrischen störungen
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (en) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd A process for the preparation of atomoxetine hydrochloride
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US20090137598A1 (en) 2007-06-21 2009-05-28 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
EP2288345B1 (de) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psychopharmazeutika
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
WO2011027359A2 (en) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
EP2348120B1 (de) 2009-12-30 2014-06-11 Universität Wien Enzymatische Reduktion von 1-Phenylpropanon und Derivate davon
JP2013535425A (ja) 2010-07-01 2013-09-12 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 心的外傷後ストレス障害を治療する方法
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
MX2013010598A (es) 2011-03-17 2014-01-08 Lupin Ltd Composiciones farmaceuticas de liberacion controlada de inhibidor de recaptacion de serotonina selectivo.
EP2879516A1 (de) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. Verwendung von fluoxetin bei tieren
US20150174083A1 (en) 2012-07-31 2015-06-25 Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine for increasing meat and milk production
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
US9802925B2 (en) 2014-03-28 2017-10-31 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Also Published As

Publication number Publication date
CS189680B2 (en) 1979-04-30
SU1005655A3 (ru) 1983-03-15
DE2500110C2 (de) 1987-06-11
RO70660B (ro) 1983-08-30
IE40346B1 (en) 1979-05-09
DK688974A (de) 1975-09-01
SE412906B (sv) 1980-03-24
CA1051034A (en) 1979-03-20
AU7683674A (en) 1976-06-24
YU37307B (en) 1984-08-31
NL181654B (nl) 1987-05-04
DE2500110A1 (de) 1975-07-17
ATA10275A (de) 1976-08-15
RO69763A (ro) 1982-02-26
CH609675A5 (de) 1979-03-15
YU121481A (en) 1983-04-27
YU36915B (en) 1984-08-31
FR2257288A1 (de) 1975-08-08
NL930108I1 (nl) 1993-10-18
GB1493961A (en) 1977-12-07
SE7500215L (de) 1975-07-11
IE40346L (en) 1975-07-10
PH11652A (en) 1978-05-08
YU3275A (en) 1982-06-18
AR205633A1 (es) 1976-05-21
YU37308B (en) 1984-08-31
DK140430C (de) 1980-01-21
NL7500186A (nl) 1975-07-14
DK140430B (da) 1979-08-27
AR205577A1 (es) 1976-05-14
ZA7532B (en) 1976-08-25
AT336000B (de) 1977-04-12
JPS5939418B2 (ja) 1984-09-22
BG60761B2 (bg) 1996-02-29
BG26192A3 (bg) 1979-02-15
US4314081A (en) 1982-02-02
FR2257288B1 (de) 1978-07-21
YU121581A (en) 1983-04-27
RO70660A (ro) 1983-09-26
NL930108I2 (nl) 1994-08-16
JPS50101333A (de) 1975-08-11
AR205578A1 (es) 1976-05-14
ES433720A1 (es) 1976-12-01
DD118613A5 (de) 1976-03-12
BG23212A3 (bg) 1977-07-12
BE824255A (fr) 1975-07-09

Similar Documents

Publication Publication Date Title
NL181654C (nl) Werkwijze ter bereiding van een farmaceutisch preparaat door een 3-methylamino-1-fenylpropylfenyletherderivaat in een geschikte toedieningsvorm te brengen, en werkwijze voor de bereiding van genoemde 3-methylamino-1-fenylpropylfenyletherderivaten.
NL186294C (nl) Werkwijze voor de vervaardiging van een foelievormig geneeskrachtig preparaat.
NL7507798A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL7503367A (nl) Werkwijze voor de bereiding van een geneesmiddel met neuro-psychotrope werking.
NL185620C (nl) Werkwijze voor het bereiden van een farmaceutisch preparaat en voor een daarvoor geschikte pyrrolidineverbinding.
NL182400C (nl) Werkwijze ter bereiding van een farmacologisch preparaat, dat ten minste een prostaanzuurderivaat bevat, alsmede werkwijze ter bereiding van prostaanzuurderivaten geschikt voor gebruik bij deze werkwijze.
NL7504216A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL7513064A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL165154C (nl) Werkwijze voor de bereiding van een reukstofcompositie door een butenonderderivaat in een voor dergelijke toepassingen geschikte vorm te brengen, alsmede werk- wijze voor de bereiding van daarvoor geschikte butenon- derivaten.
NL186383C (nl) Werkwijze voor de bereiding van octahydroindolochinolizinederivaten en werkwijze voor de bereiding van een farmaceutisch preparaat met vaatverwijdende werking, alsmede gevormd farmaceutisch preparaat.
NL7501680A (nl) Werkwijze voor de bereiding van een farmaceu- tisch preparaat.
NL162643C (nl) Werkwijze ter bereiding van een farmaceutisch preparaat, onder toepassing daarvan verkregen, gevormd farmaceutisch preparaat en werkwijze voor de bereiding van 5-fluorpyrimidineverbindingen.
NL183402C (nl) Werkwijze ter bereiding van 17alfa-ethynyl-(5alfa)-2-androsteen-17beta-ol, alsmede het acetaat daarvan, werkwijze voor de bereiding van een geneesmiddel, en het onder toepassing daarvan verkregen gevormde preparaat.
NL7506872A (nl) Werkwijze voor de bereiding van een farmaceutische preparaat.
NL7505571A (nl) Werkwijze voor de bereiding van een geneesmid- del met anti-lipolytische werking.
NL189297C (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat met antibiotische werking en werkwijze voor de bereiding van een thienamycinederivaat.
NL159378B (nl) Werkwijze voor het bereiden van 2-aminoalkyl-6-methyl-7-nitro-1,2,3,4-tetrahydrochinolinen, werkwijze voor het bereiden van een farmaceutisch preparaat, alsmede gevormd farmaceutisch preparaat.
NL7503181A (nl) Werkwijze voor de bereiding van een geneesmiddel met maag-antisecretiewerking, een dergelijk ge- neesmiddel en een werkwijze voor de bereiding van de geneeskrachtige verbindingen.
NL158075B (nl) Werkwijze voor het bereiden van een farmaceutisch preparaat, gevormd preparaat en werkwijze ter bereiding van daartoe geschikte benzodioxoolderivaten.
NL170541C (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat met celproliferatiewerking alsmede werkwijze voor de bereiding van een verbinding met celproliferatiewerking.
NL7511343A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat.
NL144923B (nl) Werkwijze voor de bereiding van een nalfa-gesubstitueerd 2-0-methyloxytocinederivaat, werkwijze ter bereiding van farmaceutische preparaten en gevormde preparaten.
NL7505202A (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat en aldus verkregen gevormde farmaceu- tische preparaten.
NL186238C (nl) Werkwijze ter bereiding van een geneesmiddel met pijnstillende en ontstekingswerende werking, op basis van 2-aminoalkoxydibenzyletherderivaten, alsmede werkwijze voor de bereiding van voor gebruik hiervoor geschikte 2-aminoalkoxydibenzyletherderivaten.
NL173850C (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat op basis van een 4a,9b-dihydro-8,9b-dimethyldibenzofuran-3-onderivaat en werkwijze voor de bereiding van daarvoor geschikte 4a,9b-dihydro-8,9b-dimethyldibenzofuran-3-onderivaten.

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
AC1 Application for a supplementary protection certificate

Free format text: 930108, 930629

SNR Assignments of patents or rights arising from examined patent applications

Owner name: ELI LILLY NEDERLAND

KC1 Grant of a supplementary protection certificate

Free format text: 930108, 950107, EXPIRES:20000106

V4 Discontinued because of reaching the maximum lifetime of a patent
AC1 Application for a supplementary protection certificate

Free format text: 0930108, 930629